Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas

Journal of the National Cancer Institute

Volumn 90, Issue 4, 1998, Pages 287-294

  Tartour, Eric ^a   Gey, Alain ^a   Sastre Garau, Xavier ^a   Surin, Isabelle Lombard ^a   Mosseri, Véronique ^a   Fridman, Wolf H ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER INVASION; CELL INFILTRATION; DIAGNOSTIC VALUE; EFFECTOR CELL; HUMAN; HUMAN TISSUE; KILLER CELL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UTERINE CERVIX CARCINOMA;

EID: 0032542524     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.4.287     Document Type: Article

References (48)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Bartholomew JS, Stacey SN, Coles B, Burt DJ, Arrand JR, Stern PL. Identification of a naturally processed HLA A0201-restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein. Eur J Immunol 1994;24:3175-9.
3. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papilloma-virus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
4. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995;25:2638-42.
5. Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, et al. Genital papillomavirus infection and cervical dysplasia - opportunistic complications of HIV infection. Int J Cancer 1992;50:45-8.
6. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
7. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A 0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-8.
8. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995;72:405-11.
9. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995;57:366-75.
10. Min W, Pober JS, Johnson DR. Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stal1 alpha. J Immunol 1996;156:3174-83.
11. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996;14:301-31.
12. Petterson F, editor. Annual report on the results of treatment in gynecological cancer. Vol 20. Stockholm: International Federation of Gynecology and Obstetrics, 1988:30-1.
13. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995;63:205-12.
14. Cromme FV, Meijer CJ, Snijders PJ, Uyterlinde A, Kenemans P, Helmerhorst T, et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 1993;67:1372-80.
15. Tartour E, Gey A, Sastre-Garau X, Pannetier C, Mosseri V, Kourilsky P, et al. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res 1994;54:6243-8.
16. Bornstein J, Lahat N, Kinarty A, Revel M, Abramovici H, Shapiro S. Interferon-beta and -gamma, but not tumor necrosis factor-alpha, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus. Cancer 1997;79:924-34.
17. Glew SS, Duggan-Keen M, Cabrera T, Stern PL. HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 1992;52:4009-16.
18. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:1478-83.
19. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995;55:3847-53.
20. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995;63:366-71.
21. Mori H, Hanabayashi T, Yamada Y, Tamaya T. Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer. J Clin Immunol 1990;10:45-51.
22. Pao CC, Yao DS, Lin CY, Lee SC, Su HT, Lin SC. Genomic aberrations of human papillomavirus recovered from cervical cancers. Biochem Biophys Res Commun 1996;222:116-20.
23. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997;89: 245-50.
24. Woodworth CD, Lichti U, Simpson S, Evans CH, DiPaolo JA. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res 1992;52:456-63.
25. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996;14:369-96.
26. Restifo NP, Spiess PJ, Karp SE, Mule JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992;175:1423-31.
27. Meyers FJ, Gumerlock PH, Kawasaki ES, Wang AM, deVere White RW, Erlich HA. Bladder cancer. Human leukocyte antigen II, interleukin-6, and interleukin-6 receptor expression determined by the polymerase chain reaction. Cancer 1991;67:2087-95.
28. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991;83:1668-72.
29. Lu C, Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS. Endogenous interleukin 6 can function as an in vivo growth stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res 1997;2:1417-25.
30. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
31. Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ Jr. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 1996;3:176-84.
32. Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 1992; 51:573-80.
33. Loeffler CM, Smyth MJ, Longo DL, Kopp WC, Harvey LK, Tribble HR, et al. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol 1992;149: 949-56.
34. Edwards RP, Kuykendall K, Crowley-Nowick P, Partridge EE, Shingleton HM, Mestecky J. T lymphocytes infiltrating advanced grades of cervical neoplasia. CD8-positive cells are recruited to invasion. Cancer 1995;76: 1411-5.
35. Bell MC, Edwards RP, Partridge EE, Kuykendall K, Conner W, Gore H, et al. CD8+ T lymphocytes are recruited to neoplastic cervix. J Clin Immunol 1995;15:130-6.
36. Erard F, Wild MT, Garcia-Sanz JA, Le Gros G, Switch of CD8 T cells to noncytolytic CD8-CD4-cells that make TH2 cytokines and help B cells. Science 1993;260:1802-5.
37. Tay SK, Jenkins D, Maddox P, Singer A. Lymphocyte phenotypes in cervical intraepithelial neoplasia and human papillomavirus infection. Br J Obstet Gynaecol 1987;94:16-21.
38. Coleman N, Stanley MA. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer 1994;56:314-9.
39. Matsushita K, Takenouchi T, Kobayashi S, Hayashi H, Okuyama K, Ochiai T. et al. HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gamma in situ and its association with tumour progression. Br J Cancer 1996;73:644-8.
40. Chen PW, Ananthaswamy HN. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 1993;151:244-55.
41. Baskar S, Clements VK,. Glimcher LH, Nabavi N, Ostrand-Rosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 1996;156:3821-7.
42. Becker JC, Brabletz T, Czerny C, Termeer C, Brocker EB. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int Immunol 1993;5:1501-8.
43. Denfeld RW, Dietrich A, Wuttig C, Tanczos E, Weiss JM, Vanscheidt W, et al. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 1995;62:259-65.
44. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.
45. Handel-Fernandez ME, Cheng X, Herbert LM, Lopez DM. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. J Immunol 1997;158:280-6.
46. Cromme FV, Meijer CJ, Snijders PJ, Uyterlinde A, Kenemans P, Helmerhorst T, et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 1993;67:1372-80.
47. Bornstein J, Ben-David Y, Atad J, Pascal B, Revel M, Abramovici H. Treatment of cervical intraepithelial neoplasia and invasive squamous cell carcinoma by interferon. Obstet Gynecol Surv 1993;48:251-60.
48. Iwasaka T, Hayashi Y, Yokoyama M, Hachisuga T, Sugimori H. Interferon gamma treatment for cervical intraepithelial neoplasia. Gynecol Oncol 1990;37:96-102.